BCM
NUVB icon

Bayesian Capital Management’s Nuvation Bio NUVB Stock Holding History

Bayesian Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-46,300
Closed -$135K – 939
2024
Q2 		$135K Buy
+46,300
New +$141K 0.02% 641

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bayesian Capital Management's NUVB Position: Q3 2024 in Review

Bayesian Capital Management sold out of Nuvation Bio (NUVB) in Q3 2024, closing a stake of 46,300 shares — an estimated $135K sold.

Bayesian Capital Management first reported a position in NUVB in Q2 2024 and held it in 1 quarter. The position peaked at $135K in Q2 2024. 154 funds tracked by Wall St. Rank hold NUVB as of Q3 2024.

  • Bayesian Capital Management reported no remaining Nuvation Bio position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 46,300 Nuvation Bio shares in Q3 2024, an estimated $135K.
  • Bayesian Capital Management first reported a position in Nuvation Bio in Q2 2024 and held it in 1 quarter.
  • Bayesian Capital Management's Nuvation Bio position peaked at $135K in Q2 2024.
  • 154 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.